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Abstract We describe a case of bowel strangulation
caused by massive peritoneal adhesion as a result of
effective chemotherapy. A 71-year-old man, who had
obstructive descending colon cancer with massive peri-
toneal metastases and, therefore, received palliative sur-
gery consisting of diverting colostomy and sampling of
peritoneal nodules, developed bowel strangulation on day 4
of the 2nd course of chemotherapy, including irinotecan,
l-leucovorin, and 5-fluorouracil. Emergent celiotomy
showed a massive intraperitoneal adhesion formed around
several intestinal loops, which were not observed at the
prior surgery. One loop was strangled, but recovered by
adhesiotomy alone. Intestinal loops were formed around
aggregates of peritoneal nodules as the centers, several of
which were then sampled. We closed the abdomen after all
intestinal loops were eradicated by total enterolysis. For-
tunately, the patient has been doing well and received
chemotherapy without recurrent bowel obstruction
10 months after the present episode. Histological findings
of the aggregates causing intestinal loops demonstrated
extensive necrosis of cancerous tissue surrounded by
fibrosis with abundant lymphocyte infiltration. These
findings were not observed in the specimen sampled before
chemotherapy, suggesting that intestinal loops were caused
by inflammatory adhesion occurring around the peritoneal
metastases as a result of effectiveness of chemotherapy.
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Abbreviations
MST Median survival time
CPM Colorectal peritoneal metastases
FOLFIRI Chemotherapy consisting of irinotecan, 5FU,
and leucovorin
CRS Cytoreductive surgery
HIPEC Hyperthermal intraperitoneal chemotherapy
Introduction
Up to the 1990s, colorectal cancer patients with peritoneal
metastases were considered terminally ill and, therefore,
these patients generally received only best supportive care in
many situations. Median survival time (MST) of these
patients was reported to be approximately 6 months, and
efficacy of chemotherapy for colorectal peritoneal metas-
tases (CPM) was reported to be disappointing, with
7-9 months of gained MST [1–5]. According to the recent
advancements in chemotherapeutic agents and/or regimens
with biological targeted agents, however, survival outcomes
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have been dramatically improved with more than 2 years of
MST [4, 5]. In other words, application of cytotoxic
chemotherapy with or without biologic targeted agents for
patients with massive CPM, who might have been consid-
ered ineligible for chemotherapy in previous decades, seems
currently common. Therefore, many adverse events which
arise from implementation of chemotherapy have been
increasingly reported and it is considered that these events
would have not developed in previous decades when
effective chemotherapeutic agents and/or regimens did not
exist [5–7].
We herein report a case of bowel strangulation due to
massive intraperitoneal adhesion as a result of effective-
ness of chemotherapy for multiple peritoneal metastases
originating from colorectal cancer.
Case presentation
A 71-year-old man was seen at our hospital for complaints
of abdominal fullness and a hard large tumor identified
palpably in the left lower abdomen. He had a history of
receiving surgery for rectal cancer, which was performed
more than 10 years previously. After careful workups,
descending colon cancer, causing bowel stenosis and
multiple peritoneal metastases, was diagnosed (Fig. 1).
Because bowel stenosis was severe, surgery was conducted
in the semi-emergent setting. Intraabdominal findings
showed that numerous peritoneal nodules and/or clusters of
nodules were observed all over the abdomen and huge
omental mass formed by peritoneal nodules occupied in the
upper abdomen. Primary lesion was considered to be
removable. However, R0 resection seemed impossible due
to the massive peritoneal metastases accounting for Peri-
toneal Cancer Index [8] with 26 and Peritoneal Surface
Disease Severity of Colon Cancer with Peritoneal Dis-
semination [9] with 11 points and Stage IV. Therefore, we
decided to perform diverting colostomy and sampling
peritoneal nodules. Because of huge omental mass, trans-
verse colostomy was impractical. Thus, we mobilized the
ascending colon for the colostomy and sampled several
peritoneal nodules. Fortunately, intestinal obstruction was
not observed other than the primary stenotic lesion in spite
of massive peritoneal metastases at that time.
Postoperative course was uneventful, and chemotherapy
consisting of irinotecan, 5FU, and leucovorin (FOLFIRI)
was started on postoperative day 7 and given biweekly.
Any severe adverse effects, such as watery diarrhea,
refractory constipation, or uncontrollable nausea, were not
found other than mild anorexia until day 4 (25 days after
surgery) of the 2nd course of FOLFIRI, when the patient
developed sudden abdominal fullness causing epigastric
pain and vomiting. Findings of abdominal X-ray and CT
suggested intestinal obstruction (Fig. 2). Furthermore,
strangulation of the intestine was strongly suspected based
on the physical, laboratory, and imaging findings at that
time. Hence, urgent celiotomy was conducted. The abdo-
men was easily opened because the intraabdominal organs
scarcely adhered to the abdominal wall. Intraabdominal
findings showed that the number and sizes of peritoneal
nodules and/or clusters of nodules seemed markedly
reduced. However, several intestinal loops were observed,
and each loop was formed around a cluster of nodules at
the center. One of the intestinal loops was mildly discol-
ored by the strangulation (Fig. 3). Adhesions causative of
these intestinal loops seemed not derived from prior sur-
gical procedures because these intestinal loops did not
adhere to the dissection surfaces, which were formed in
prior surgery. Each nodule or cluster of nodules caused
moderate to severe adhesion, but the adhesion was relea-
sable with adhesiotomy alone although total enterolysis
was necessary for eradicating all intestinal loops. After
that, discolored intestine recovered normal color and nor-
mal peristalsis was observed throughout the abdomen. We
washed the peritoneal cavity using warm saline and laid
several sheets of bioresorbable hyaluronic acid/car-
boxymethylcellulose membrane [10] extensively in the
abdomen. Then we closed the abdominal wall after sam-
pling several peritoneal nodules, which caused intestinal
loops. Fortunately, postoperative course was uneventful
and the patient was discharged from hospital 7 days after
the second urgent surgery and thereafter received
chemotherapy again.
Histology findings of peritoneal nodules sampled at the
second urgent surgery showed that cancerous tissue was
nearly eradicated and fibrous tissue was formed surround-
ing the peritoneal nodules (Fig. 4). Furthermore, inflam-
matory cell infiltration, which was mainly composed of
lymphocytes, was observed extensively in the fibrous tis-
sue. In other words, each peritoneal metastatic nodule was
encapsulated with fresh fibrous tissue, through which
mononuclear cell infiltration was diffusely observed. It
seems that surrounding intraabdominal structures were
attched to each cluster of peritoneal metastatic nodules by
the fibrous tissue. These findings were not observed in the
peritoneal nodules sampled at the first celiotomy (Fig. 4),
which was performed before chemotherapy, suggesting
that formation of intestinal loops was caused by inflam-
matory adhesion occurring around the peritoneal metas-
tases as a result of effectiveness of chemotherapy. Serum
carcinoembryonic antigen and carbohydrate antigen 19-9
levels, both of which were measured before induction of
chemotherapy and after the episode of bowel strangulation,
reduced from 7.2 ng/ml to 1.0 ng/ml and from 48.8 IU/ml
to 35.5 IU/ml, respectively. These results also supported
the effectiveness of chemotherapy.
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Fortunately, the patient has been doing well and receiving
chemotherapy with targeted agent (bevacizumab), which
was added from the 4th course, 10 months after the diag-
nosis of descending colon cancer without recurrent intestinal
obstruction. At this stage, efficacy of chemotherapy was
judged to be partial response of Response Evaluation Cri-
teria in Solid Tumors version 1. 1 [11].
Discussion
During last 15 years, markedly effective cytotoxic
chemotherapies and biological targeted agents were devel-
oped and prognosis of patients with unresectable colorectal
cancer has been dramatically improved. However, although
peritoneal metastasis is the second most frequent distant
metastasis of colorectal cancer following liver metastasis,
treatment outcomes of patients with CPM were dismal in the
previous decades when no effective drugs were present other
than 5-fluorouracil [1–5, 7–10, 12]. Recently, new
chemotherapeutic and targeted agents have improved the
prognosis of these patients although treatment outcome
seemed still unsatisfactorywith systemic chemotherapy alone
[7–10, 12]. Furthermore, cytoreductive surgery (CRS) with
hyperthermal intraperitoneal chemotherapy (HIPEC) for
CPM was introduced in the 1990s [13]. This aggressive
approach for CPM has been gaining wider acceptance and
thus being standardized [5, 7–10, 12]. Current stance of
applyingCPSwithHIPEC for CPMhas been establishedwith
effective chemotherapy as a prerequisite [5, 7–10, 12].
Therefore, indication of induction chemotherapy for CPM
will expand and, therefore, application of chemotherapy
accompanied by the standardization ofCRSwithHIPECmust
be increasingly given for patients with CPM [5–7, 10, 12].
Based on the comparison of histological findings
between peritoneal nodules sampled before and after the
induction of chemotherapy in the present case, bowel
strangulation was considered to result from the effect of
chemotherapy, which was essentially beneficial, but not
adverse. It was reported that tumor cell death induced intra-
and/or peri-tumoral inflammatory cell infiltration, mainly
composed of lymphocyte, for scavenging necrotic tumor
Fig. 1 Findings of barium enema, colonoscopy, and abdominal
computed tomography. a A severely stenotic lesion (white arrow-
heads) was observed in the descending colon just proximal to the
sigmoid-descending junction. b A large circular type 2 lesion was
detected by colonoscopy and caused severe bowel stenosis. c,
d Greater omentum was occupied with numerous peritoneal nodules
(black arrows) and formed an omental cake. Moderate ascites was
identifiable. e Primary lesion was easily detectable as a large mass by
computed tomography (large white arrow)
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tissue [14, 15]. In other words, the cause of massive peri-
toneal adhesion in the present case can be explainable as
follows. Administration of chemotherapy caused necrosis
of cancerous tissue and subsequent lymphocyte infiltration
around the peritoneal metastatic nodules, which were
intended to scavenge necrotic tumor tissue and conse-
quently brought on inflammatory reaction surrounding the
nodules [14, 15]. The inflammatory reaction formed
fibrosis around the peritoneal metastases. In the present
case, peritoneal metastases were severe and extended
throughout the abdomen. Thus, inflammatory reaction
caused by effectiveness of chemotherapy occurred
throughout the abdomen and resulted in massive peritoneal
adhesion. To the best of our knowledge, there has been no
Fig. 2 Findings of abdominal
X-ray and computed
tomography taken at the onset
of bowel strangulation.
a Abnormal intestinal gases
(black arrows) observed by
abdominal X-ray suggested
formation of several intestinal
loops. b Dilated intestine was
observed in the right upper
abdomen. c, d Dilatation of the
intestine was tapered (white
arrow) and disrupted by the
severe caliber change (white
arrowhead). These findings
suggested that bowel
strangulation was caused by the
torsion of the intestinal loop
Fig. 3 Photograph and
schematic image of
intraabdominal findings
schematic image at the second
emergent laparotomy. a Dilated
and mildly discolored ileum was
found in the right upper
abdomen. b Intestinal loops
were formed around the
aggregates of peritoneal
metastatic nodules as the centers
(small and large black arrows).
Notably, one loop was twisted
on the aggregate at the axis
(large black arrows) and
strangled
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report describing this condition. Hence, we should consider
this case to be unusual. However, in the modern era of
effective chemotherapy, in which indication and applica-
tion of chemotherapy have expanded, we must be aware
that not only adverse effects, but also effectiveness of
chemotherapy may lead to serious complications and,
therefore, this condition, i.e., massive peritoneal adhesion
as a result of effective chemotherapy, should be always
taken into account when patients with multiple peritoneal
metastases are treated by chemotherapy.
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Fig. 4 Comparison of histological findings between peritoneal nod-
ules before and after chemotherapy. a–c Loupe image (a original
magnification, 95), low-power (b original magnification, 940), and
high-power maicroscopic findings (c original magnification, 9100) of
the specimens sampled at the first semi-emergent surgey, i.e., before
receiving chemotherapy, showed that peritoneal nodules were mainly
composed of well-differentiated tubular adenocarcinoma and in part
mucin-enriched cancerous cells, which leads to the diagnossis of well
differentiated mucinous carcinoma. d–f Loupe image (d origincal
magnification, 95), low-power (b, e original magnification, 940),
and high-power maicroscopic findings (f original magnification,
9100) of the specimens sampled at emregent surgery for bowel
strangulation, i.e., after two courses of chemotherapy, showed that
peritoneal nodules were occupied mainly with abundant mucous lake
and a little viable canceraous tissue was observed sparsely in the
mucous lake. Each nodule was encapsulated with fresh fibrous tissue,
through which mononuclear cell infiltration was diffusely observed. It
seems that the fibrous tissue attached surrounding mesothelial
membranous structures to peritoneal metastatic nodules
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